Clinical Trial Update: Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of Daclizumab High Yield Process for relapsing-remitting multiple sclerosis completed. Results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Daclizumab High Yield Process (DAC HYP) (daclizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2016-07-11